UNSPSC 51386302: Pirprofen

This classification denotes a phenylpropionate and non-steroidal anti-inflammatory agent with the molecular formula C13H14ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T7KN291890, chemically known as hydratropic acid, 3-chloro-4-(3-pyrrolin-1-yl)- but generally known as pirprofen, which bears US NIH Compound Identifier 35935. European Medicines Agency schedules Pirprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09940MIG.

UNSPSC 51386302 Pirprofen is a Commodity code that in practice captures state and local procurement of pharmaceutical products and related health-supply systems rather than the specific active pharmaceutical ingredient the code nominally names. Recent state and local solicitations under this code show health agencies and cooperative purchasing alliances buying naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and RFP processes. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances serving government facilities across multiple states. Work solicited under the code centers on annual or multi-year supply contracts with fixed pricing, quarterly or ongoing deliveries to specified locations, compliance with FDA and Drug Supply Chain Security Act requirements, and vendor qualifications including current Good Manufacturing Practices certification, insurance coverage, and E-Verify employment eligibility verification.

Activity under the code spans Florida, Texas, and Minnesota-led multistate arrangements, with geographic reach extending to states participating in cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs as preliminary market research before formal RFP issuance. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating jurisdictions including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; vendors must maintain relationships with authorized wholesalers and pay a three percent administrative fee on purchases.